The influence of nutritional status, lipid profile, leptin concentration and polymorphism of genes encoding leptin and neuropeptide Y on the effectiveness of immunotherapy in advanced NSCLC patients.
Humans
Leptin
/ genetics
Neuropeptide Y
/ genetics
Male
Female
Carcinoma, Non-Small-Cell Lung
/ genetics
Middle Aged
Lung Neoplasms
/ genetics
Immunotherapy
/ methods
Aged
Nutritional Status
Obesity
/ genetics
Adult
Lipids
/ blood
Polymorphism, Genetic
B7-H1 Antigen
/ genetics
Treatment Outcome
Aged, 80 and over
Immunotherapy
Leptin
Lipid profile
Non-small cell lung cancer
Obesity
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
received:
06
06
2024
accepted:
26
07
2024
medline:
2
8
2024
pubmed:
2
8
2024
entrez:
1
8
2024
Statut:
epublish
Résumé
Neuropeptide Y is a neurotransmitter in the nervous system and belongs to the orexigenic system that increases appetite. Its excessive secretion leads to obesity. Leptin is a pro-inflammatory adipokine (produced in adipose tissue) induced in obesity and may mediate increased antitumor immunity in obesity (including the promotion of M1 macrophages). Leptin and neuropeptide Y gene polymorphisms, causing increased leptin levels and the occurrence of obesity, and lipid profile disorders, may increase the effectiveness of immunotherapy. In 121 patients with advanced NSCLC without mutations in the EGFR gene and rearrangements of the ALK and ROS1 genes, undergoing immunotherapy (1st and 2nd line of treatment) or chemoimmunotherapy (1st line of treatment), we assessed BMI, lipid profile, PD-L1 expression on cancer cells using the immunohistochemical method (clone SP263 antibody), leptin concentration in blood serum by ELISA, polymorphisms in the promoter region of the genes for leptin (LEP) and neuropeptide Y (NPY) by real-time PCR. Leptin concentration was significantly higher in obese patients than in patients with normal or low weight (p = 0.00003) and in patients with disease stabilization compared to patients with progression observed during immunotherapy (p = 0.012). Disease control occurred significantly more often in patients with the GA or AA genotype than patients with the GG genotype in the rs779039 polymorphism of the LEP gene. The median PFS in the entire study group was five months (95% CI: 3-5.5), and the median OS was 12 months (95% CI: 8-16). Median PFS was highest in patients with TPS ≥ 50% (6.5 months) and in obese patients (6.6 months). Obese patients also had a slightly longer median OS compared to other patients (23.8 vs. 13 months). The multivariate Cox logistic regression test showed that the only factor reducing the risk of progression was TPS ≥ 50% (HR = 0.6068, 95% CI: 0.4001-0.9204, p = 0, 0187), and the only factor reducing the risk of death was high leptin concentration (HR = 0.6743, 95% CI: 0.4243-1.0715, p = 0.0953). Assessment of nutritional status, serum leptin concentration and polymorphisms in the LEP gene may be of additional importance in predicting the effectiveness of immunotherapy and chemoimmunotherapy in patients with advanced NSCLC.
Identifiants
pubmed: 39090596
doi: 10.1186/s12885-024-12716-6
pii: 10.1186/s12885-024-12716-6
doi:
Substances chimiques
Leptin
0
Neuropeptide Y
0
LEP protein, human
0
Lipids
0
B7-H1 Antigen
0
CD274 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
937Informations de copyright
© 2024. The Author(s).
Références
Chen S, Mellan I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10.
doi: 10.1016/j.immuni.2013.07.012
pubmed: 23890059
Rangamuwa K, et al. Methods for assessment of the tumour microenvironment and immune interactions in non-small cell lung cancer. A narrative review. Front Oncol. 2023;13:1129195. https://doi.org/10.3389/fonc.2023.1129195 .
doi: 10.3389/fonc.2023.1129195
pubmed: 37143952
pmcid: 10151669
Genova C, et al. Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade. Front Immunol. 2021;12:799455. https://doi.org/10.3389/fimmu.2021.799455 .
doi: 10.3389/fimmu.2021.799455
pubmed: 35069581
Bleve A, Durante B, Sica A, Consonni FM. Lipid metabolism and cancer immunotherapy: immunosuppressive myeloid cells at the crossroad. Int J Mol Sci. 2020;21:5845. https://doi.org/10.3390/ijms21165845 .
doi: 10.3390/ijms21165845
pubmed: 32823961
pmcid: 7461616
Cancer Today. Globocan 2022 (version 1.1) – 08.02.2024. https://gco.iarc.fr/today/en/dataviz/pie?mode=cancer& group_populations=1&sexes=0&types=0.
Wang F, Xia T, Li Z, Gao X, Fang X. Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer. Front Oncol. 2023;13:1213297. https://doi.org/10.3389/fonc.2023.1213297 .
doi: 10.3389/fonc.2023.1213297
pubmed: 37727216
pmcid: 10505960
Lee SM, et al. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study. Lancet. 2023;402:451–63. https://doi.org/10.1016/S0140-6736(23)00774-2 .
doi: 10.1016/S0140-6736(23)00774-2
pubmed: 37423228
Cortellini A, et al. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: a post hoc analysis of the phase 3 OAK trial. Cancer. 2022;128:3067–79. https://doi.org/10.1002/cncr.34348 .
doi: 10.1002/cncr.34348
pubmed: 35727053
Chen M, et al. Comparison of chemotherapy plus pembrolizumab vs. chemotherapy alone in EGFR-mutant non-small-cell lung cancer patients. Clin Lung Cancer. 2023;24:278–86. https://doi.org/10.1016/j.cllc.2022.12.003 .
doi: 10.1016/j.cllc.2022.12.003
pubmed: 36635116
Rounis K, et al. Cancer cachexia and antitumor immunity: common mediators and potential targets for new therapies. Life (Basel). 2022;12:880. https://doi.org/10.3390/life12060880 .
doi: 10.3390/life12060880
pubmed: 35743911
Potapov I, Kanneganti TD, del Sol A. Fostering experimental and computational synergy to modulate hyperinflammation. Trends Immunol. 2022;43:78–92. https://doi.org/10.1016/j.it.2021.11.004 .
doi: 10.1016/j.it.2021.11.004
Cheng T, Zhang J, Liu D, Lai G, Wen X. Prognosis of non-small-cell lung cancer patients with lipid metabolism pathway alternations to immunotherapy. Front Genet. 2021;12:646362. https://doi.org/10.3389/fgene.2021.646362 .
doi: 10.3389/fgene.2021.646362
pubmed: 34335679
pmcid: 8317604
Wang Z, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019;25:141–51. https://doi.org/10.1038/s41591-018-0221-5 .
doi: 10.1038/s41591-018-0221-5
pubmed: 30420753
Pereira S, Cline DL, Glavas MM, Covey SD, Kieffer TJ. Tissue-specific effects of leptin on glucose and lipid metabolism. Endocr Rev. 2021;42:1–28. https://doi.org/10.1210/endrev/bnaa027 .
doi: 10.1210/endrev/bnaa027
pubmed: 33150398
Kim JW, Kim JH, Lee YJ. The role of adipokines in tumor progression and its association with obesity. Biomedicines. 2024;12:97. https://doi.org/10.3390/biomedicines12010097 .
doi: 10.3390/biomedicines12010097
pubmed: 38255203
pmcid: 10813163
Harris RB. Direct and indirect effects of leptin on adipocyte metabolism. Biochim Biophys Acta. 2014;1842:414–23. https://doi.org/10.1016/j.bbadis.2013.05.009 .
doi: 10.1016/j.bbadis.2013.05.009
pubmed: 23685313
Vita E, et al. Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC). Cancer Immunol Immunother. 2023;72:3803–12. https://doi.org/10.1007/s00262-023-03533-0 .
doi: 10.1007/s00262-023-03533-0
pubmed: 37668709
pmcid: 10576666
Jais A, Brüning JC. Arcuate nucleus-dependent regulation of metabolism-pathways to obesity and diabetes mellitus. Endocr Rev. 2022;43:314–28. https://doi.org/10.1210/endrev/bnab025 .
doi: 10.1210/endrev/bnab025
pubmed: 34490882
Abella V, et al. Leptin in the interplay of inflammation, metabolism and immune system disorders. Nat Rev Rheumatol. 2017;13:100–9. https://doi.org/10.1038/nrrheum.2016.209 .
doi: 10.1038/nrrheum.2016.209
pubmed: 28053336
Jia Z, Liu Y, Cui S. Adiponectin induces breast cancer cell migration and growth factor expression. Cell Biochem Biophys. 2014;70:1239–45. https://doi.org/10.1007/s12013-014-0047-9 .
doi: 10.1007/s12013-014-0047-9
pubmed: 24906235
Ray A, Cleary MP. The potential role of leptin in tumor invasion and metastasis. Cytokine Growth Factor Rev. 2017;38:80–97. https://doi.org/10.1016/j.cytogfr.2017.11.002 .
doi: 10.1016/j.cytogfr.2017.11.002
pubmed: 29158066
pmcid: 5720178
Kloting N, Bluher M. Adipocyte dysfunction, inflammation and metabolic syndrome. Rev Endocr Metab Disord. 2014;15:277–87. https://doi.org/10.1007/s11154-014-9301-0 .
doi: 10.1007/s11154-014-9301-0
pubmed: 25344447
Wrann CD, et al. Short-term and long-term leptin exposure differentially affect human natural killer cell immune functions. Am J Physiol Endocrinol Metab. 2012;302:E108–16. https://doi.org/10.1152/ajpendo.00057.2011 .
doi: 10.1152/ajpendo.00057.2011
pubmed: 21952038
Tsiotra PC, Boutati E, Dimitriadis G, Raptis SA. High insulin and leptin increase resistin and inflammatory cytokine production from human mononuclear cells. Biomed Res. Int 2013, 487081 (2013). https://doi.org/10.1155/2013/487081
Pérez-Pérez A, Sánchez-Jiménez F, Vilariño-García T, Sánchez-Margalet V. Role of leptin in inflammation and vice versa. Int J Mol Sci. 2020;21:5887. https://doi.org/10.3390/ijms21165887 .
doi: 10.3390/ijms21165887
pubmed: 32824322
pmcid: 7460646
Afrin S, Ramaiyer M, Begum UAM, Borahay MA. Adipocyte and adipokines promote a uterine leiomyoma friendly microenvironment. Nutrients. 2023;15:715. https://doi.org/10.3390/nu15030715 .
doi: 10.3390/nu15030715
pubmed: 36771423
pmcid: 9919329
Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol. 2006;207:12–22. https://doi.org/10.1002/jcp.20472 .
doi: 10.1002/jcp.20472
pubmed: 16110483
Zou Y, Yu X, Zhou C, Zhu C, Yuan Y. Adverse effects of low serum lipoprotein cholesterol on the immune microenvironment in gastric cancer: a case-control study. Lipids Health Dis. 2022;21:150. https://doi.org/10.1186/s12944-022-01766-z .
doi: 10.1186/s12944-022-01766-z
pubmed: 36585674
pmcid: 9805280
Munoz-Erazo L, Rhodes JL, Marion VC, Kemp RA. Tertiary lymphoid structures in cancer - considerations for patient prognosis. Cell Mol Immunol. 2020;17:570–5. https://doi.org/10.1038/s41423-020-0457-0 .
doi: 10.1038/s41423-020-0457-0
pubmed: 32415259
pmcid: 7264315
Cheng N, et al. Prognostic value of tumor-infiltrating lymphocytes and tertiary lymphoid structures in Epstein-Barr virus-associated and -negative gastric carcinoma. Front Immunol. 2021;12:692859. https://doi.org/10.3389/fimmu.2021.692859 .
doi: 10.3389/fimmu.2021.692859
pubmed: 34276684
pmcid: 8281029
Li Q, et al. CD8(+) T cells located in tertiary lymphoid structures are associated with improved prognosis in patients with gastric cancer. Oncol Lett. 2020;20:2655–64. https://doi.org/10.3892/ol.2020.11828 .
doi: 10.3892/ol.2020.11828
pubmed: 32782582
pmcid: 7400769
Hao M, et al. Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy. Sci Transl Med. 2020;12:eaaz6667. https://doi.org/10.1126/scitranslmed.aaz6667 .
doi: 10.1126/scitranslmed.aaz6667
pubmed: 33239389
Liu C, et al. Oxysterols direct B-cell migration through EBI2. Nature. 2011;475:519–23. https://doi.org/10.1038/nature10226 .
doi: 10.1038/nature10226
pubmed: 21796211
Wen H, et al. Body mass index, weight change, and cancer prognosis: a meta-analysis and systematic review of 73 cohort studies. ESMO Open. 2024;9:102241. https://doi.org/10.1016/j.esmoop.2024.102241 .
doi: 10.1016/j.esmoop.2024.102241
pubmed: 38442453
pmcid: 10925937
Scherübl H. Metabolic syndrome and cancer risk. Dtsch Med Wochenschr. 2022;147:1068–77. https://doi.org/10.1055/a-1868-9164 .
doi: 10.1055/a-1868-9164
pubmed: 35970189
Liu J, Wang R, Tan S, Zhao X, Hou A. Association between insulin resistance, metabolic syndrome and its components and lung cancer: a systematic review and meta-analysis. Diabetol Metab Syndr. 2024;16:63. https://doi.org/10.1186/s13098-024-01308-w .
doi: 10.1186/s13098-024-01308-w
pubmed: 38468310
pmcid: 10926619
Jasinski-Bergner S, Kielstein H. Adipokines regulate the expression of tumor-relevant microRNAs. Obes Facts. 2019;12:211–25. https://doi.org/10.1159/000496625 .
doi: 10.1159/000496625
pubmed: 30999294
pmcid: 6547259
Tomaszewski W, Sanchez-Perez L, Gajewski TF. Brain tumor microenvironment and host state: implications for immunotherapy. Clin Cancer Res. 2019;25:4202–10. https://doi.org/10.1158/1078-0432.CCR-18-1627 .
doi: 10.1158/1078-0432.CCR-18-1627
pubmed: 30804019
pmcid: 6635001
Murphy WJ, Longo DL. The surprisingly positive association between obesity and cancer immunotherapy efficacy. JAMA. 2019;321:1247–8. https://doi.org/10.1001/jama.2019.0463 .
doi: 10.1001/jama.2019.0463
pubmed: 30882850
Kichenadasse G, et al. Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. JAMA Oncol. 2020;6:512–8. https://doi.org/10.1001/jamaoncol.2019.5241 .
doi: 10.1001/jamaoncol.2019.5241
pubmed: 31876896
Lee JH, et al. Obesity paradox in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy. J Cachexia Sarcopenia Muscle. 2023;14:2898–907. https://doi.org/10.1002/jcsm.13367 .
doi: 10.1002/jcsm.13367
pubmed: 37964713
pmcid: 10751411
Guo H, et al. Prognostic value of obesity in patients with cancer treated with immune checkpoint inhibitors: an updated meta-analysis and systematic review. Mol Clin Oncol. 2024;20:5. https://doi.org/10.3892/mco.2023.2703 .
doi: 10.3892/mco.2023.2703
pubmed: 38125744
Rocco D, et al. Prognostic factors in advanced non-small cell lung cancer patients treated with immunotherapy. Cancers. 2023;15:4684. https://doi.org/10.3390/cancers15194684 .
doi: 10.3390/cancers15194684
pubmed: 37835378
pmcid: 10571734
Sánchez-Jiménez F, Pérez-Pérez A, de la Cruz-Merino L, Sánchez-Margalet V. Obesity and breast cancer: role of leptin. Front Oncol. 2019;9:596. https://doi.org/10.3389/fonc.2019.00596 .
doi: 10.3389/fonc.2019.00596
pubmed: 31380268
pmcid: 6657346
Hahn AW, Venkatesh N, Msaoeul P, McQuade JL. The influence of obesity on outcomes with immune checkpoint blockade: clinical evidence and potential biological mechanisms. Cells. 2023;12:2551. https://doi.org/10.3390/cells12212551 .
doi: 10.3390/cells12212551
pubmed: 37947629
pmcid: 10649394
Zhang T, Li S, Chang J, Qin Y, Ii C. Impact of BMI on the survival outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. BMC Cancer. 2023;23:1023. https://doi.org/10.1186/s12885-023-11512-y .
doi: 10.1186/s12885-023-11512-y
pubmed: 37872469
pmcid: 10594865
Palmer JP, et al. Overweight or obese patients may take longer to respond and be less responsive to immune checkpoint inhibitors in non-small cell lung cancer: a retrospective review. J Clin Oncol. 2021;39:e21209. https://doi.org/10.1200/JCO.2021.39.15_suppl.e21209 .
doi: 10.1200/JCO.2021.39.15_suppl.e21209
Antoun S, et al. Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle. Eur J Cancer. 2023;178:49–59. https://doi.org/10.1016/j.ejca.2022.10.013 .
doi: 10.1016/j.ejca.2022.10.013
pubmed: 36403367
Dudzinski SO, et al. Leptin augments antitumor immunity in obesity by repolarizing tumor-associated macrophages. J Immunol. 2021;207:3122–30. https://doi.org/10.4049/jimmunol.2001152 .
doi: 10.4049/jimmunol.2001152
pubmed: 34772698
Zhang J, et al. The baseline serum lipid levels and outcomes of NSCLC patients receiving immunotherapy combined of non-combined with radiotherapy: a single center retrospective study. Int J Radiat Oncol. 2023;117:e11.
doi: 10.1016/j.ijrobp.2023.06.670
Liu L, et al. Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non-small-cell lung cancer. Lipids Health Dis. 2024;23:16. https://doi.org/10.1186/s12944-023-01960-7 .
doi: 10.1186/s12944-023-01960-7
pubmed: 38218878
pmcid: 10787985
Terrasi M, et al. Functional analysis of the – 2548G/A leptin gene polymorphism in breast cancer cells. Int J Cancer. 2009;125:1038–44. https://doi.org/10.1002/ijc.24372 .
doi: 10.1002/ijc.24372
pubmed: 19408304
Marcello MA et al. Polymorphism in LEP and LEPR may modify leptin levels and represent risk factors for thyroid cancer. Int. J. Endocrinol 2015, 73218 (2015). https://doi.org/10.1155/2015/173218
Mohamed AA, et al. The impact of LEP rs7799039 polymorphism and obesity on the severity of coronavirus disease-19. Diabetes Metab Syndr Obes. 2023;16:515–22. https://doi.org/10.2147/DMSO.S391869 .
doi: 10.2147/DMSO.S391869
pubmed: 36852180
pmcid: 9961580
Shetty SS, Kumari N, Hegde P, Roopashree PG, Suhasini PC. Leptin gene polymorphism rs7799039; G2548A, metabolic and oxidative stress markers in polycystic ovarian syndrome. J King Saud Univ Sci. 2022;34:102222. https://doi.org/10.1016/j.jksus.2022.102222 .
doi: 10.1016/j.jksus.2022.102222
Guo S, Liu M, Wang G, Torroella-Kouri M, Gonzalez-Perez RR. Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta Rev Cancer. 2012;1825:207–22. https://doi.org/10.1016/j.bbcan.2012.01.002 .
doi: 10.1016/j.bbcan.2012.01.002
Kim SM, et al. Association of leptin receptor polymorphisms Lys109Arg and Gln223Arg with serum leptin profile and bone mineral density in Korean women. Am J Obstet Gynecol. 2008;198:1–8. https://doi.org/10.1016/j.ajog.2007.10.799 .
doi: 10.1016/j.ajog.2007.10.799